PE20240227A1 - Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos - Google Patents

Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos

Info

Publication number
PE20240227A1
PE20240227A1 PE2023001843A PE2023001843A PE20240227A1 PE 20240227 A1 PE20240227 A1 PE 20240227A1 PE 2023001843 A PE2023001843 A PE 2023001843A PE 2023001843 A PE2023001843 A PE 2023001843A PE 20240227 A1 PE20240227 A1 PE 20240227A1
Authority
PE
Peru
Prior art keywords
children
myopia
progression
inhibitor
eye drops
Prior art date
Application number
PE2023001843A
Other languages
English (en)
Spanish (es)
Inventor
Kazuo Tsubota
Toshihide Kurihara
Shinichi Ikeda
Kiwako Mori
Xiaoyan Jiang
Original Assignee
Tsubota Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsubota Lab Inc filed Critical Tsubota Lab Inc
Publication of PE20240227A1 publication Critical patent/PE20240227A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
PE2023001843A 2020-12-11 2021-09-01 Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos PE20240227A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020205489 2020-12-11
PCT/JP2021/032067 WO2022123836A1 (ja) 2020-12-11 2021-09-01 小児の近視進行抑制用点眼剤及び小児の近視進行抑制剤のスクリーニング方法

Publications (1)

Publication Number Publication Date
PE20240227A1 true PE20240227A1 (es) 2024-02-16

Family

ID=81973514

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001843A PE20240227A1 (es) 2020-12-11 2021-09-01 Gotas para los ojos para inhibir la progresion de la miopia en ninos y metodos de cribado del inhibidor de la progresion de la miopia en ninos

Country Status (15)

Country Link
US (1) US20240041806A1 (https=)
EP (1) EP4257147A4 (https=)
JP (1) JPWO2022123836A1 (https=)
KR (1) KR20230135054A (https=)
CN (1) CN116761595A (https=)
AU (1) AU2021396680A1 (https=)
CA (1) CA3204753A1 (https=)
CL (1) CL2023001634A1 (https=)
IL (1) IL303499A (https=)
MA (1) MA61683A1 (https=)
MX (1) MX2023006723A (https=)
PE (1) PE20240227A1 (https=)
TN (1) TN2023000138A1 (https=)
TW (1) TW202237075A (https=)
WO (1) WO2022123836A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019501945B1 (en) * 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
CN107898793B (zh) * 2017-12-01 2019-12-24 温州医科大学 一种抑制近视的方法及制备药物的应用
JP7474706B2 (ja) * 2018-12-18 2024-04-25 参天製薬株式会社 4-フェニル酪酸を含有する老視の治療または予防剤

Also Published As

Publication number Publication date
JPWO2022123836A1 (https=) 2022-06-16
WO2022123836A1 (ja) 2022-06-16
CA3204753A1 (en) 2022-06-16
AU2021396680A9 (en) 2024-05-30
TN2023000138A1 (en) 2025-01-02
US20240041806A1 (en) 2024-02-08
MX2023006723A (es) 2023-09-21
EP4257147A1 (en) 2023-10-11
TW202237075A (zh) 2022-10-01
KR20230135054A (ko) 2023-09-22
MA61683A1 (fr) 2023-08-31
IL303499A (en) 2023-08-01
EP4257147A4 (en) 2024-11-06
AU2021396680A1 (en) 2023-07-06
CL2023001634A1 (es) 2024-02-02
CN116761595A (zh) 2023-09-15

Similar Documents

Publication Publication Date Title
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
CO2021014292A2 (es) Moduladores de la vía de respuesta integrada al estrés
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2018003492A1 (es) Hepatitis b agentes antivirales.
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR075028A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
CR20150487A (es) Compuestos de biaril-amida como inhibidores de cinasa
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY32848A (es) Compuestos heterocíclicos de oxima
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
ECSP10010506A (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
Cunha et al. Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice
MX2021012904A (es) Moduladores de la via de respuesta al estres integrada.
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada